Additionally, NF-κB inhibitor Celastrol significantly reduced fasting blood glucose and glycosylated hemoglobin, as well as serum creatinine and urinary albumin excretion rate in db/db diabetic mice [16], suggesting that inhibition of NF-κB activation might play an indispensable role in preventing the progression of DN. The gene discussed is NFKB1; the disease is liver dysplastic nodule.